Sort
261,768 grants matching “gene therapy”
Iduronidase Replacement Therapy of the Brain in Hurler's Syndrome
$982,874Ruben J. Boado · Armagen Technologies, Inc. · U44 · FY2010 · NS
Models for Vision Research
$982,702Patsy M Nishina · Jackson Laboratory · R01 · FY2011 · EY
Models for Vision Research
$982,702Patsy M Nishina · Jackson Laboratory · R01 · FY2012 · EY
Clinical Analysis Of Disorders Of Hearing And Balance
$982,665Carmen Crowell Brewer · National Institute On Deafness And Other Communication Disorders · ZIA · FY2013 · DC
A Precision Medicine for Alcohol-Associated Liver Disease
$982,659Wanqing Liu · Genetobe Inc. · UT2 · FY2024 · AA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2016 · CA
Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastases
$982,500Joel S. Bader · Johns Hopkins University · U01 · FY2020 · CA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2021 · CA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2020 · CA
New Paradigms for Targeting Truncal Driver Mutations
$982,500William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2017 · CA
Pathway Discovery and Target Validation for Outgrowth of Breast Cancer Metastases
$982,500Joel S. Bader · Johns Hopkins University · U01 · FY2021 · CA
Expanding the Market and Success Rates for Myeloablative Cancer Treatments Using PUL-042, an Innate Immune Stimulant
$982,488Brenton Scott · Pulmotect, Inc · R44 · FY2015 · HL
Novel Plasmodial Surface Anion Channel Inhibitors as Antimalarial Drugs
$982,478Michelle M. Butler · Microbiotix, Inc · R44 · FY2021 · AI
Molecular Epidemiology of Colorectal Cancer
$982,470Stephen B Gruber · University Of Michigan At Ann Arbor · R01 · FY2007 · CA
Evaluating the impact of novel inhibitors of nuclear pore export in SLE
$982,411Douglas G. Widman · Karyopharm Therapeutics, Inc. · R44 · FY2019 · AI
Multiplexed, Non-Amplified, Nucleic Acid-Based Identification of Multidrug Resistant Pathogens Using an Integrated Optofluidic Platform
$982,407Aaron R. Hawkins · Brigham Young University · R01 · FY2019 · AI
Novel DNA Repair Inhibitors for Cancer Therapy
$982,379Peter M Glazer · Yale University · R35 · FY2023 · CA
Gene therapy for SCID-X1 with low dose busulfan and a SIN-lentiviral vector
$982,311David A Williams · Boston Children'S Hospital · U01 · FY2020 · AI
Viral And Cellular Factors Governing Efficient Gene Delivery
$982,268Maribeth V. Eiden · National Institute Of Mental Health · ZIA · FY2011 · MH
Northwestern University O'Brien Kidney National Resource Center
$982,232Susan E Quaggin · Northwestern University At Chicago · U54 · FY2024 · DK
Nipah & Hendra Virus Nonhuman Primate Model & Therapeutics Development
$982,178Thomas William Geisbert · University Of Texas Med Br Galveston · U01 · FY2010 · AI
Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes
$982,162Daniel J Lerner · Senseion Therapeutics, Inc. · R44 · FY2024 · HL
Targeting mutant estrogen receptor driven breast cancers
$982,110Ganesh V Raj · Etirarx, Llc · R44 · FY2021 · CA
Overcoming Drug Resistance in Multiple Myeloma
$982,082Peter Leif Bergsagel · Mayo Clinic Arizona · U54 · FY2021 · CA
AsthmaNet: Brigham and Women's Hospital & Children's Hospital Boston
$981,959Elliot Israel · Brigham And Women'S Hospital · U10 · FY2010 · HL